Does Blue Cross of Idaho Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Forteo is the brand name for teriparatide, a synthetic 34-amino-acid fragment of human parathyroid hormone manufactured by Eli Lilly. Unlike bisphosphonates such as alendronate (Fosamax) or risedronate (Actonel), which slow bone resorption, teriparatide actively stimulates osteoblasts to build new bone. That anabolic mechanism makes it one of the most effective agents available for severe osteoporosis, but it also makes it one of the most expensive.

The FDA approved Forteo for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis [1]. Because the drug carries a black-box warning regarding osteosarcoma risk observed in rat studies (at doses 3 to 60 times the human dose), the FDA limits use to 24 cumulative months in a patient's lifetime [2].

Those two factors, high price and a lifetime cap, shape every insurance policy that covers the drug.

How Teriparatide Fits into the Osteoporosis Treatment Ladder

Most payers, including Blue Cross of Idaho, classify anabolic agents like Forteo as second-line or third-line therapy. First-line agents are oral bisphosphonates, which cost as little as $4 per month as generics. A 2022 American Association of Clinical Endocrinology (AACE) guideline states: "Bisphosphonates remain the preferred initial pharmacologic treatment for most patients with osteoporosis due to their established efficacy, safety record, and low cost" [3].

Insurers use that guideline language to build step-therapy requirements. A prescriber generally needs to show that:

• The patient tried and failed (or fractured while on) a bisphosphonate, or
• A bisphosphonate is contraindicated (e.g., creatinine clearance <35 mL/min, esophageal dysmotility, or documented intolerance), or
• The patient has very severe disease, such as a T-score below -3.0 with multiple vertebral fractures.

The Biosimilar and Generic Field in 2025

Teriparatide's patent exclusivity ended, and two FDA-approved teriparatide products, Bonsity (TransEnterix) and Tlando (not to be confused with the testosterone product), are now available. Blue Cross of Idaho may preferentially cover one of these lower-cost versions over branded Forteo on commercial formularies in 2025. Patients whose physicians prescribed brand-name Forteo specifically may need a brand-medically-necessary exception if the plan mandates a generic-first policy.

Blue Cross of Idaho Plan Types and How Formularies Differ

Blue Cross of Idaho operates several distinct product lines, and Forteo coverage rules are not uniform across all of them.

Commercial Individual and Small Group Plans (ACA Marketplace)

On the Idaho health insurance exchange (Your Health Idaho), Blue Cross of Idaho offers Silver, Gold, and Bronze metal-tier plans. Specialty drugs like Forteo are almost universally placed on Tier 4 or Tier 5. Coinsurance on specialty tiers commonly runs 30 to 50 percent after the deductible, which on a $3,200 list-price drug can mean $960 to $1,600 per month before copay assistance.

Prior authorization is required. The plan's published clinical criteria for anabolic osteoporosis agents generally mirror the AACE 2022 guidelines and require DXA-documented T-scores, fracture history documentation, and evidence of bisphosphonate trial or contraindication.

Blue Cross of Idaho Medicare Advantage Plans

Medicare Part D formularies must comply with CMS rules for protected drug classes. Osteoporosis agents are not a CMS-protected class, so Blue Cross of Idaho Medicare Advantage plans can (and do) apply prior authorization and step therapy.

For Medicare beneficiaries in 2025, the Inflation Reduction Act caps out-of-pocket drug costs at $2,000 per year under Part D, which meaningfully reduces the catastrophic cost exposure that previously made Forteo unaffordable for many seniors [4]. Still, prior authorization requirements apply, and the step-therapy requirement for a bisphosphonate trial remains in most Medicare Advantage formularies.

Blue Cross of Idaho Federal Employee Program (FEP)

Federal employees covered under the BCBS Federal Employee Program follow a separate national formulary. Forteo is covered under FEP with prior authorization, and the FEP's PharmacyCare program places it on a specialty tier with a per-fill cost share that varies by plan option (Basic vs. Standard).

Fully Insured vs. Self-Funded Employer Plans

Large employers sometimes self-insure and use Blue Cross of Idaho only for administrative services (an ASO arrangement). In those cases, the employer sets the formulary. Forteo coverage terms for self-funded plans can differ substantially from Blue Cross of Idaho's standard commercial formulary. Patients should confirm their specific plan documents, the Summary of Benefits and Coverage (SBC), before assuming standard commercial rules apply.

Prior Authorization Criteria: What Blue Cross of Idaho Typically Requires

Prior authorization for Forteo under Blue Cross of Idaho commercial plans generally tracks the following clinical thresholds. These are drawn from published specialty pharmacy criteria and AACE/NOF guidelines, as individual plan documents are proprietary.

Bone Mineral Density Documentation

A DXA scan showing a T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck is the baseline threshold. Patients with a T-score between -1.0 and -2.5 (osteopenia range) may qualify if they have a documented low-trauma fracture of the hip or vertebra, which is consistent with the National Osteoporosis Foundation criteria for initiating pharmacologic therapy [5].

The DXA scan should be recent, generally within 24 months of the PA submission date. A FRAX score (10-year fracture probability) above 3 percent for hip fracture or above 20 percent for major osteoporotic fracture can support approval even when T-scores are borderline.

Step Therapy: Bisphosphonate Requirement

This is the most common reason initial Forteo PAs are denied. The plan needs evidence of one of the following:

1. At least 12 months of bisphosphonate therapy (alendronate, risedronate, ibandronate, or zoledronic acid) with documented failure, defined as a fracture or significant bone density decline while adherent to therapy.
2. A documented adverse effect or intolerance, such as severe esophagitis, osteonecrosis of the jaw, or atypical femoral fracture.
3. A contraindication per FDA labeling, such as renal impairment with creatinine clearance <35 mL/min for oral bisphosphonates.

Glucocorticoid-induced osteoporosis is a common exception pathway. Patients on prednisone 7.5 mg/day or higher for 3 or more months with a T-score <-1.5 and a history of fracture often qualify for first-line Forteo without a bisphosphonate trial, consistent with the 2022 ACR glucocorticoid-induced osteoporosis guidelines [6].

Lifetime Duration Limit

Blue Cross of Idaho, like virtually all payers, enforces the FDA's 24-month lifetime limit. The PA approval will be issued for 12 months at a time, with a renewal PA required at month 12. At the 24-month mark, therapy must stop, and the prescriber should transition the patient to an antiresorptive agent such as denosumab or a bisphosphonate to preserve the bone gains made during Forteo therapy. Failure to transition is associated with rapid bone loss, a pattern documented in the VERO trial and follow-up observational data [7].

How to Submit a Forteo Prior Authorization with Blue Cross of Idaho

Step 1: Gather the Clinical Documentation Package

Before submitting, the prescribing provider should compile:

• A recent DXA report with T-scores at lumbar spine and hip.
• Office notes documenting fracture history, including radiology reports.
• A list of prior osteoporosis medications with dates of use, doses, and reason for discontinuation.
• Lab results including serum calcium, creatinine (with estimated GFR), and vitamin D levels.
• A clinical statement explaining why Forteo is indicated over alternatives.

A complete submission package reduces the back-and-forth with the plan and shortens time to decision, which Blue Cross of Idaho targets at 72 hours for standard PAs and 24 hours for urgent requests.

Step 2: Use the Blue Cross of Idaho Provider Portal

Providers can submit PAs electronically through the Blue Cross of Idaho provider portal at bcidaho.com, through CoverMyMeds, or via fax. Electronic submission through the portal typically receives faster turnaround than fax. The prescribing physician's NPI, the patient's member ID, and the drug's HCPCS or NDC code for teriparatide must be included.

Step 3: Respond Promptly to Additional Information Requests

The plan's pharmacy benefit manager may issue a request for additional clinical information (a "pend" rather than a denial). Responding within 5 business days prevents the request from auto-denying.

Step 4: Request a Peer-to-Peer If Denied

If the PA is denied, the prescribing physician has the right to request a peer-to-peer review with the plan's medical director or a consulting physician. This call typically runs 15 to 20 minutes. Published data from specialty pharmacy audits suggest peer-to-peer reviews overturn initial denials in 40 to 60 percent of cases for specialty osteoporosis agents, though Blue Cross of Idaho's specific rate is not publicly disclosed.

What Forteo Actually Costs Under Blue Cross of Idaho

List Price vs. What Patients Pay

The 2024 wholesale acquisition cost (WAC) for a single Forteo pen (28-day supply, 2.4 mL, delivering 20 mcg per day) is approximately $3,200. On a Tier 4 specialty plan with 40 percent coinsurance and a $5,000 deductible, a patient could owe more than $3,000 in January before any deductible credit accumulates.

Eli Lilly Forteo Savings Card

Eli Lilly's Forteo Savings Card is available to commercially insured patients (not Medicare or Medicaid). The card can reduce the monthly cost share to as low as $0 per month for eligible patients, with a program maximum benefit that Lilly adjusts annually. Enrollment is at forteo.com/savings. As of early 2025, the card covers up to $150 per 28-day fill for patients who still owe a copay after insurance.

HealthRX Clinical Note on Copay Cards and Accumulator Adjustments

A critical point that many patients miss: Blue Cross of Idaho commercial plans may use a copay accumulator adjustment program, meaning the manufacturer's copay card payments do not count toward the patient's deductible or out-of-pocket maximum. Once the copay card benefit is exhausted, the patient's full cost share resumes. Patients should confirm with Blue Cross of Idaho member services (1-800-627-1188) whether their specific plan uses accumulator or maximizer logic before assuming year-round $0 copays. This framework for evaluating copay card value applies equally to Tymlos (abaloparatide), Prolia (denosumab), and Evenity (romosozumab) when covered under specialty tiers.

Patient Assistance Program (for Uninsured or Underinsured)

Lilly Cares Foundation offers Forteo at no cost to qualifying uninsured patients with household incomes at or below 400 percent of the federal poverty level. Applications are submitted at lillycares.com or by calling 1-800-545-5979.

Alternatives If Blue Cross of Idaho Denies Forteo

A denial is not the end of the road. Several clinical and administrative options exist.

Tymlos (Abaloparatide)

Abaloparatide (Tymlos, Radius Health) is a parathyroid hormone-related protein analog approved for postmenopausal osteoporosis at high fracture risk. In the ACTIVE trial (N=2,463), abaloparatide reduced new vertebral fractures by 86 percent vs. Placebo over 18 months [8]. Because it works through a similar mechanism as teriparatide, Blue Cross of Idaho's PA criteria for Tymlos are almost identical to those for Forteo. However, Tymlos may be preferred on some formularies if it carries a lower tier placement or lower negotiated price.

Romosozumab (Evenity)

Romosozumab (Evenity, Amgen) is a sclerostin inhibitor with both anabolic and antiresorptive properties, approved for postmenopausal women at high fracture risk. In the FRAME trial (N=7,180), romosozumab reduced vertebral fractures by 73 percent vs. Placebo over 12 months [9]. Evenity is given as two subcutaneous injections monthly for 12 months only, administered in a clinical setting. It carries a boxed warning for cardiovascular events and is contraindicated within the preceding year of a myocardial infarction or stroke. Some Blue Cross of Idaho formularies place Evenity in a more favorable tier than Forteo, making it a practical alternative when the cardiovascular risk profile is acceptable.

Denosumab (Prolia)

For patients who cannot access anabolic therapy, denosumab (Prolia, Amgen) 60 mg subcutaneously every 6 months is a potent antiresorptive option. Prolia is covered by Medicare Part B (physician-administered) rather than Part D, which changes the cost-sharing structure entirely for Medicare beneficiaries.

Formal Appeals

Blue Cross of Idaho must provide a written denial with the specific clinical reason. Patients have the right to a first-level internal appeal, a second-level appeal, and then an independent external review under Idaho state insurance law. The Idaho Department of Insurance oversees this process. External reviews are decided by an independent organization and are binding on the insurer.

How Effective Is Forteo? A Brief Clinical Summary

Understanding the evidence helps patients and providers make the case in a peer-to-peer review.

Fracture Risk Reduction

The key Fracture Prevention Trial (N=1,637 postmenopausal women with prior vertebral fractures) showed that teriparatide 20 mcg/day reduced new vertebral fractures by 65 percent and nonvertebral fractures by 53 percent vs. Placebo over a median of 21 months [10]. Bone mineral density at the lumbar spine increased by a mean of 9.7 percent at 18 months.

Glucocorticoid-Induced Osteoporosis

In a head-to-head trial comparing teriparatide vs. Risedronate in glucocorticoid-induced osteoporosis (N=428), teriparatide produced significantly greater lumbar spine BMD gains and a lower incidence of new vertebral fractures at 18 months (P<0.001) [11]. This trial is the most commonly cited evidence in PA peer-to-peer calls for steroid-induced disease.

Post-Forteo Therapy Transition

A sequential therapy approach, Forteo followed by denosumab, has shown additive BMD gains in the DATA-Switch trial. Transitioning to an antiresorptive agent after completing 24 months of teriparatide is standard of care and should be documented in the patient's care plan at the time of PA submission to demonstrate long-term management planning.

Practical Checklist for Patients Navigating Blue Cross of Idaho Forteo Coverage

Keep this list accessible during the coverage process:

• Confirm your specific plan name and group number (shown on your insurance card).
• Ask your prescriber whether a DXA scan is on file and whether it is recent enough (within 24 months).
• Request that your prescriber document all prior osteoporosis medications in the PA submission, including start and stop dates.
• Enroll in the Forteo Savings Card before your first fill, not after a denial.
• Ask Blue Cross of Idaho member services whether your plan uses a copay accumulator adjustment program.
• If denied, request the specific denial reason in writing within 24 hours of the decision.
• Ask your prescriber to initiate a peer-to-peer review call within 10 business days of denial (deadlines vary).
• Contact the Idaho Department of Insurance at (800) 721-3272 if internal appeals are exhausted.